Bisphenol A interacts with the estrogen receptor α in a distinct manner from estradiol

We investigated the interaction of bisphenol A (BPA, an estrogenic environmental contaminant used in the manufacture of plastics) with the estrogen receptor alpha (ERalpha) transfected into the human HepG2 hepatoma cell line and expanded the study in vivo to examine the effect of BPA on the immature rat uterus. Bisphenol A was 26-fold less potent in activating ER-WT and was a partial agonist with the ERalpha compared to E2. The use of ERalpha mutants in which the AF1 or AF2 regions were inactivated has permitted the classification of ER ligands into mechanistically distinct groups. The pattern of activity of BPA with the ERalpha mutants differed from the activity observed with weak estrogens (estrone and estriol), partial ERalpha agonists (raloxifene or 4-OH-tamoxifen), or a pure antagonist (ICI 182, 780). Intact immature female Sprague-Dawley rats were exposed to BPA alone or with E2 for 3 days. Unlike E2, BPA had no effect on uterine weight; however, like E2, both peroxidase activity and PR levels were elevated, though not to the level induced by E2. Following simultaneous administration, BPA antagonized the E2 stimulatory effects on both peroxidase activity and PR levels but did not inhibit E2-induced increases of uterine weight. These results demonstrate that BPA is not merely a weak estrogen mimic but exhibits a distinct mechanism of action at the ERalpha.

[1]  B. Katzenellenbogen,et al.  Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[3]  L. E. Romine,et al.  Effects of wild type and mutant estrogen receptors on DNA flexibility, DNA bending, and transcription activation. , 1996, Molecular endocrinology.

[4]  J. McLachlan,et al.  A yeast estrogen screen for examining the relative exposure of cells to natural and xenoestrogens. , 1996, Environmental health perspectives.

[5]  The developmental toxicity of bisphenol A in rats and mice. , 1987, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[6]  K. Korach,et al.  Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. , 1993, Molecular endocrinology.

[7]  B. Howard,et al.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells , 1982, Molecular and cellular biology.

[8]  N. Koszewski,et al.  Hormone- and DNA-binding mechanisms of the recombinant human estrogen receptor. , 1993, Biochemistry.

[9]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[10]  L. Gianaroli,et al.  Molecular and cellular endocrinology , 1992, Molecular and Cellular Endocrinology.

[11]  R. Bigsby,et al.  The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. , 1997, Endocrinology.

[12]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[13]  J. Gustafsson,et al.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.

[14]  J. Pike,et al.  Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.

[15]  N. Olea,et al.  Xenoestrogens released from lacquer coatings in food cans. , 1995, Environmental health perspectives.

[16]  D G Hoel,et al.  Medical hypothesis: xenoestrogens as preventable causes of breast cancer. , 1993, Environmental health perspectives.

[17]  K. Korach,et al.  Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. , 1996, Endocrinology.

[18]  N. Webster,et al.  The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.

[19]  Division on Earth Guide for the Care and Use of Laboratory Animals , 1996 .

[20]  B. Katzenellenbogen,et al.  Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.

[21]  C Sonnenschein,et al.  The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. , 1995, Environmental health perspectives.

[22]  S. Koike,et al.  Molecular cloning and characterization of rat estrogen receptor cDNA. , 1987, Nucleic acids research.

[23]  C. Portier,et al.  Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. , 1997, Toxicology and applied pharmacology.

[24]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[25]  D. Williams,et al.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.

[26]  F. Olea-Serrano,et al.  Estrogenicity of resin-based composites and sealants used in dentistry. , 1996, Environmental health perspectives.

[27]  R M Sharpe,et al.  Gestational and lactational exposure of rats to xenoestrogens results in reduced testicular size and sperm production. , 1995, Environmental health perspectives.

[28]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[29]  B. Katzenellenbogen,et al.  Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. , 1982, Journal of steroid biochemistry.

[30]  V. Jordan,et al.  Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. , 1987, Cancer research.

[31]  B. O’Malley,et al.  Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Willson,et al.  Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. , 1997, Endocrinology.

[33]  M. Tzukerman,et al.  Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.

[34]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[35]  K. Korach,et al.  Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  N. Olea,et al.  The E-screen assay: a comparison of different MCF7 cell stocks. , 1995, Environmental health perspectives.

[37]  D. Feldman,et al.  Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. , 1993, Endocrinology.

[38]  E. Kalkhoven,et al.  Negative Interaction between the RelA(p65) Subunit of NF-B and the Progesterone Receptor (*) , 1996, The Journal of Biological Chemistry.

[39]  G. W. Davis,et al.  Evaluation of a New Reproductive Toxicology Protocol Using Diethylstilbestrol (DES) as a Positive Control Compound , 1985 .

[40]  A. Soto,et al.  Developmental effects of endocrine-disrupting chemicals in wildlife and humans. , 1993, Environmental health perspectives.

[41]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .

[42]  A. Philips,et al.  Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells. , 1993, Endocrinology.

[43]  Elisabeth Scheer,et al.  Distinct classes of transcriptional activating domains function by different mechanisms , 1990, Cell.

[44]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.